ReviewCurrent HIV/AIDS reports2019
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
Review in Current HIV/AIDS reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Promoting HIV care continuum outcomes among people who use drugs and alcohol: a systematic review of randomized trials evaluating behavioral HIV care interventions published from 2011 to 2023.BMC public health · 2023Pooled it
- The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review.Journal of substance abuse treatment · 2021Pooled it
- The impact of the communities that HEAL intervention on the provision of jail-based medication for opioid use disorder & linkage programs at release: Results from a randomized, wait-list controlled trial.Journal of substance use and addiction treatment · 2026Trial
- Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder.Substance abuse · 2023Trial
- Self-reported and Point-of-Care Biomarkers of Substance Use Measures Among Older Adults with HIV from Low- and Middle-Income Countries.AIDS and behavior · 2026Article
- Implementation opportunities for optimizing retention on buprenorphine treatment for people with opioid use disorder in West Virginia.Drug and alcohol dependence · 2025Article
- A mixed-method exploratory assessment of provider-based stigma of opioid use disorder (OUD) and support for medications for opioid use disorder (MOUD) in carceral settings.Harm reduction journal · 2025Article
- Pilot of Methadone for Recently Incarcerated People with Human Immunodeficiency Virus and Opioid Use in South Africa.Journal of correctional health care : the official journal of the National Commission on Correctional Health Care · 2025Article
- Perceptions of People Who Inject Drugs About Long-acting Medications for Opioid Use Disorder, Preexposure Prophylaxis, and Antiretroviral Therapy.Open forum infectious diseases · 2025Article
- Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time among People with HIV in the Current Treatment Era.AIDS and behavior · 2025Article
- Centering autonomy and choice to support oral PrEP utilization among people who inject drugs: qualitative lessons from HPTN 094 INTEGRA.Addiction science & clinical practice · 2024Article
- Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.AIDS and behavior · 2024Article
- The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections.Drug and alcohol dependence · 2024Article
- HIV and Substance Use Disorders.Infectious disease clinics of North America · 2024Review
- HIV status and substance use disorder treatment need and utilization among adults in the United States, 2015-2019: Implications for healthcare service provision and integration.Journal of substance use and addiction treatment · 2024Article
- Past-Year HIV Testing, Current Antiretroviral Therapy Use, and Participation in Services for People Who Inject Drugs.AIDS and behavior · 2024Article
- Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia.The International journal on drug policy · 2024Article
- Provider perspectives on screening and treatment for opioid use disorder and mental health in HIV care: A qualitative study.PloS one · 2024Article
- Joint effects of substance use disorders and recent substance use on HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014-2019.Addiction (Abingdon, England) · 2023Article
- Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.Addiction science & clinical practice · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewRecent HIV outbreaks have occurred as a result of the current US opioid epidemic. Providing medications for opioid use disorder (MOUD) with methadone, buprenorphine, and extended-release naltrexone is essential to achieving optimal HIV treatment outcomes including viral suppression and retention in treatment. This review describes the pharmacology of MOUD with specific attention to interactions with antiretroviral therapy, and to the effect of MOUD on HIV treatment outcomes. RECENT
findingsMethadone and buprenorphine both improve HIV viral suppression, adherence to antiretroviral therapy, and overall mortality for persons with opioid use disorder (OUD). Extended-release naltrexone has been most extensively studied in persons with HIV leaving incarcerated settings, and improves HIV viral suppression in that context. Strategies that integrate MOUD and HIV treatment are crucial to optimize viral suppression. The differing pharmacokinetic and delivery characteristics of these MOUD offer diverse options. Given the chronic and relapsing nature of both HIV and OUD, long-term approaches are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.